Drug intelligence / Profile preview

Polyserp-P

Development stage: Unknown
Lead developer: Polyserp Therapeutics
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

Polyserp-P (also known as POLYSERP Pan-Africa) is a polyvalent equine-derived antivenom developed by Polyserp Therapeutics for the treatment of snake envenomation in Africa. It consists of F(ab')2 immunoglobulin fragments obtained from horses immunized against the venoms of 25 medically significant African snake species. These include the Boomslang (*Dispholidus typus*), burrowing asps (*Atractaspis* spp.), and 23 other species. The antivenom works by binding to and neutralizing the various toxins present in the snake venoms, preventing their systemic effects. It is currently approved for use in Africa.

Brand names: POLYSERP Pan-Africa
Other names: POLYSERP Pan-Africa

Targets

DTV (Boomslang venom toxins)

Beyond the preview

Go deeper on Polyserp-P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polyserp-P.

Explore the full profile